Steroids in Duchenne muscular dystrophy: From clinical trials to genomic research

Neuromuscular Disorders

Volumn 12, Issue SUPPL., 2002, Pages

  Muntoni, Francesco ^a   Fisher, Ivan ^a,b   Morgan, Jennifer E ^a   Abraham, David ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Royal Free Campus ^*  (United Kingdom)

Author keywords

Clinical trial; Duchenne muscular dystrophy; Gene profiling; mdx mouse; Steroids

Indexed keywords

COMPLEMENTARY DNA; CORTICOSTEROID; MESSENGER RNA; PREDNISOLONE; STEROID; STRUCTURAL PROTEIN;

CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DISEASE MODEL; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL MOUSE; GENE EXPRESSION; GENE FUNCTION; GENOMICS; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; MUSCLE STRENGTH; NONHUMAN; NORTHERN BLOTTING; OPEN STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEROID THERAPY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANIMALS; GENE EXPRESSION PROFILING; GLUCOCORTICOIDS; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDNISOLONE; RNA, MESSENGER;

EID: 0036824144     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(02)00101-3     Document Type: Conference Paper

References (25)

1. Manzur A.Y. Medical management and treatment of Duchenne muscular dystrophy. Emery A. The muscular dystrophies. 2001;Oxford University Press, Oxford.
2. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomised double-blind six month trial of prednisone in Duchenne muscular dystrophy. N Engl J Med. 320:(24):1989;1592-1597.
3. Pandya S., Myers G., Moxley R.T. Effect of daily prednisone on independent ambulation in patients with Duchenne muscular dystrophy treated up to 15 years. World Muscle Society Congress, Snowbird, Salt Lake City, Utah, 5-8th September (abstract). Neuromuscul Disord. 11:2001.
4. Dubowitz V. 47th ENMC International workshop: treatment of muscular dystrophy, 13-15 Dec 1996, Naarden, The Netherlands. Neuromuscul Disord. 7:1997;261-267.
5. Dubowitz V. 75th ENMC International workshop: Treatment of muscular dystrophy, Baarn, The Netherlands, 10-12 Dec 1999. Neuromuscul Disord. 10:2000;313-320.
6. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 41:1877;1874-1991.
7. Sansome A., Royston P., Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord. 3:(5-6):1993;567-569.
8. Dubowitz V., Kinali M., Main M., Mercuri E., Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol. 6:(3):2002;153-159.
9. Guerriero V. Jr, Florini J.R. Dexamethasone effects on myoblast proliferation and differentiation. Endocrinology. 106:(4):1980;1198-1202.
10. Passaquin A.C., Metzinger L., Leger J.J., Warter J.M., Poindron P. Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. J Neurosci Res. 35:(4):1993;363-372.
11. Rifai Z., Welle S., Moxley R.T., Lorenson M., Griggs R.C. Effect of prednisolone on protein metabolism in Duchenne dystrophy. Am J Physiol. 268:1995;67-74.
12. Jacobs S.C., Bootsma A.L., Willems P.W., Bar P.R., Wokke J.H. Prednisolone can protect against exercise-induced muscle damage. J Neurol. 243:1996;410-416.
13. Takagi A., Watanabe T., Kojima S., Endo Y. Effect of long-term administration of prednisolone on serum creatine kinase and muscle pathology of mdx mouse. Rinsho Shinkegaku (Clin Neurol). 38:1998;724-728.
14. Burrow K.L., Coovert D.D., Klein C.J., et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology. 41:(5):1991;661-666.
15. Weller B., Massa R., Karpati G., Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx muscles. Muscle Nerve. 14:(8):1991;771-774.
16. Metzinger L., Passaquin A.C., Leijendekker W.J., Poindron P., Ruegg U.T. Modulation by prednisolone of calcium handling in skeletal muscle cells. Br J Pharmacol. 116:1995;2811-2816.
17. Vandebrouck C., Imbert N., Dupont G., Cognard C., Raymond G. The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells. Neurosci Lett. 269:(9):1999;110-114.
18. Kissel J.T., Burrow K.L., Rammohan K.W., Mendell J.R. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology. 41:(5):1991;667-672.
19. Kissel J.T., Lynn J., Rammhan K., et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology. 43:(3):1993;532-536.
20. Griggs R.C., Moxley R.T. 3rd, Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 43:(3):1993;520-527.
21. Hudecki M.S., Pollina C.M., Granchelli J.A., et al. Strength and endurance in the therapeutic evaluation of prednisolone-treated mice. Res Commun Chem Pathol Pharmacol. 79:(1):1993;45-60.
22. Granchelli J.A., Pollina C., Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord. 10:2000;235-239.
23. Porter J.D., Khanna S., Kaminsiki H.J., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin deficient mdx muscle. Hum Mol Genet. 11:2002;263-272.
24. Chen Y.W., Zhao P., Borup R., Hoffman E.P. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 11:2000;1321-1336.
25. Tkatchenko A.V., Pietu G., Cros N., et al. Identification of altered gene expression in skeletal muscle from Duchenne muscular dystrophy patients. Neuromuscul Disord. 11:2001;269-277.